市場調査レポート

商品コード

1800876

片頭痛治療薬の市場レポート：治療タイプ別、薬剤タイプ別、投与経路別、流通チャネル別、地域別、2025～2033年

Migraine Drugs Market Report by Treatment Type, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033

出版日: 2025年08月01日
発行: IMARC
ページ情報: 英文 123 Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF & Excel (Single User License)

USD 2,999 447,600円

レポートPDFおよびExcelを1名のみがご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペースト、印刷はできません。

PDF & Excel (5 User License)

USD 3,999 596,850円

レポートPDFおよびExcelを同一企業内の5名様までがご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペーストはできませんが、印刷は5部まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Corporate License)

USD 4,999 746,100円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペーストは可能ですが、事前にIMARC Services Private Limited社の許可が必要です。PDFおよびExcelの印刷回数に制限はありません。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=149.25円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の片頭痛治療薬の市場規模は2024年に44億米ドルに達しました。今後、IMARC Groupは、2033年までに市場は65億米ドルに達し、2025～2033年にかけて4.06%の成長率（CAGR）を示すと予測しています。世界の片頭痛治療薬市場の成長は、片頭痛に対する理解の深まり、治療プロセスに関する知識の拡大、CGRPベースの薬剤のような治療法の開発、予防的治療の促進、新興市場での拡大機会の高まりによって大きく牽引されています。さらに、北米は疾患の有病率が高いため、最大の地域となっています。

片頭痛治療薬市場は、効果的な薬物療法に対する需要の高まりに対応するために発展を続けており、大きな変革期を迎えています。また、ヘルスケアへのアクセスの向上が片頭痛治療薬市場の成長に大きく寄与しています。特に先進国ではヘルスケアのインフラが変化し続けているため、片頭痛治療薬の利用可能性が高まっています。ほとんどの国では、保険適用や償還政策の改善を通じて片頭痛治療薬の利用可能性を高めており、患者はより新しく効果的な治療を受けられるようになっています。特に新興国市場では、健康保険制度の普及が進んでいることも、処方薬需要を押し上げています。ヘルスケアインフラが急速に開発されている国では、片頭痛治療へのアクセスが増加しており、これが市場の成長を支えています。

片頭痛治療薬市場の動向

認識と診断の高まり

片頭痛とその深刻な後遺症に対する認識の高まりが、片頭痛薬の需要を押し上げています。その有病率に関しては、未診断または十分な治療を受けていない患者が依然として多くいます。毎年6月になると、世界中の頭痛コミュニティが、片頭痛に対する一般大衆の意識を高めるために活動しています。効果的な治療法の必要性を認識する人が増えるにつれて、治療法への需要も高まり、市場の成長を牽引しています。片頭痛研究財団は、3,900万人以上のアメリカ人が片頭痛に苦しんでおり、女性は男性の3倍も片頭痛を経験しやすいと述べています。片頭痛が深刻な健康問題であるという認識が高まるにつれ、片頭痛患者と医師の両方が最も有望な片頭痛治療法のバリエーションを探すよう促されています。

医薬品開発の進歩

医薬品開発と科学の絶え間ない進歩が市場の成長に寄与しています。製薬業界では、片頭痛患者のための新しい治療法の研究開発（R&D）が重要な仕事の1つとなっています。これには、新しいデリバリーシステムや薬剤形態の利用など、より効果的で安全性が高く、投与方法の点でも優れた薬剤の応用が含まれます。さらに、片頭痛治療に関する臨床試験が複数進行中または計画中であり、研究界が治療法の追求に全力を注いでいるという印象を強めています。それぞれの発見が新たな市場機会を生み出し、患者にとって様々な代替療法が利用可能になり、治療法の改善が進むことで、片頭痛患者の生活水準が向上しています。研究機関もまた、片頭痛の治療法を進歩させるために、セミナーや討論会を行っています。例えば、米国神経学会（AAN）は、2025年4月5日～9日までカリフォルニア州サンディエゴで2025年度年次総会を開催し、急性片頭痛の治療について討議しました。

片頭痛患者の増加

世界の片頭痛患者数の増加が、片頭痛治療薬の需要を牽引しています。ストレス、ライフスタイルの変化、環境因子などの要因により、片頭痛を患う人が増加しているという報告が後を絶ちません。片頭痛が病気であるという認識が高まるにつれ、治療を受ける人が増え、片頭痛治療薬市場を牽引しています。医療従事者は、効果的で集中的な治療の必要性をますます認識するようになっており、片頭痛管理用に特別に設計された新薬の誕生につながっています。また、片頭痛はさまざまな年齢層に及びますが、主に働き盛りの成人に影響を及ぼすため、労働時間の損失という経済的圧力が政府やヘルスケアシステムに治療の成功を優先するよう促しています。2024年にMedscapeが発表した論文によると、米国では年間3,000万人以上が1回以上の片頭痛を経験しています。このような診断例の着実な増加が、片頭痛治療薬市場における医薬品イノベーションの必要性を高めており、予防的治療と急性期治療の両方が使用量を増加させています。

片頭痛治療薬市場の促進要因

ヘルスケア支出の増加

世界のヘルスケア支出の増加は、片頭痛治療薬市場の動向を好転させています。政府や民間のアプローチは、医療システムや社会に短期的な影響を与えることが証明されている片頭痛のような疾患の予防と管理にますます資金を集中させています。加えて、世界のヘルスケア支出は増加の傾向をたどっており、その多くは慢性的な疾患管理に対処するためです。その結果、ヘルスケア産業製品や治療薬へのアクセスが増え、片頭痛治療薬のニーズが高まっています。この動向は、片頭痛がますます蔓延している新しい市場において最も高く、その結果、片頭痛の症状を治療するために提供する治療法や治療法という点で、製薬会社に特別な機会を生み出しています。

健康のためのデジタルソリューションの統合

デジタルヘルスソリューションの導入拡大は、市場成長を強化する主要な要因の1つであり、その成長は続いています。モバイルアプリ、ウェアラブル、遠隔医療プラットフォームは、片頭痛にとって不可欠な管理ツールになりつつあります。これらのデジタルプラットフォームは、食べ物、ストレスレベル、環境条件など、さまざまな片頭痛の誘因を監視する手段を患者に提供し、その後、個別に治療を行います。片頭痛の発作や関連症状を継続的に追跡することで、患者は自分の状態をよりよく理解し、治療をより遵守できるようになります。さらに、遠隔医療プラットフォームによってヘルスケア専門家との遠隔相談が容易になり、特に農村部や十分なサービスを受けていない地域での専門家へのアクセスが増加しています。これらの技術はまた、患者が自分の病状をよりよくコントロールすることを可能にし、QOLと全体的な治療成果を高めています。デジタルヘルス技術の進歩により、従来の薬物療法が補強され、片頭痛に対するより緊密でデータ情報に基づいた治療が可能になります。このような技術が通常の治療の一部となることで、患者の活性化が促進され、特にこのようなデジタルツールで調整や追跡が可能な片頭痛治療薬へのニーズが今後も高まると思われます。

予防治療へのシフト

片頭痛の治療は、急性緩和から予防治療へとシフトしており、片頭痛治療薬市場の成長に決定的な影響を与えています。片頭痛の治療法は主に発作時の緩和に向けられていました。しかし、片頭痛の病態に関する知識が進歩するにつれて、医療従事者は発作の頻度や重症度を減少させる予防療法に重点を置くようになっています。この変化は、片頭痛の再発が患者のQOLに大きな影響を与えること、そして予防的治療が長期的な効果を著しく高めることを認識するようになったことによって促進されています。片頭痛の予防療法における最も重要なブレークスルーのひとつは、カルシトニン遺伝子関連ペプチド（CGRP）阻害剤の創製です。これらの生物学的製剤は、片頭痛発作の頻度を減少させ、慢性片頭痛に苦しむ患者に長期的な救済を提供する上で、非常に大きな可能性があることが証明されています。片頭痛の発症に関与する特定の分子メカニズムを特異的に標的とすることにより、CGRP阻害剤は片頭痛治療の新時代をもたらし、既存の治療法よりも有効性が向上し、副作用が軽減される標的メカニズムを提供します。

北米
- 米国
- カナダ
アジア太平洋地域
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- インドネシア
- その他
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- ロシア
- その他
ラテンアメリカ
- ブラジル
- メキシコ
- その他
中東・アフリカ

第11章 SWOT分析

第12章バリューチェーン分析

第13章ポーターのファイブフォース分析

第14章価格分析

第15章競合情勢

市場構造
主要企業
主要企業のプロファイル
- Abbott Laboratories
- Allergan Plc（Abbvie Inc.）
- Amgen Inc.
- AstraZeneca Plc
- Bausch Health Companies Inc.（formerly Valeant Pharmaceuticals）
- Eisai Co. Ltd.
- Eli Lilly and Company
- Endo International Plc
- GlaxoSmithKline Plc
- Johnson & Johnson
- Merck & Co.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Teva Pharmaceutical Industries Limited

図表

List of Figures

Figure 1: Global: Migraine Drugs Market: Major Drivers and Challenges
Figure 2: Global: Migraine Drugs Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Migraine Drugs Market: Breakup by Treatment Type (in %), 2024
Figure 4: Global: Migraine Drugs Market: Breakup by Drug Type (in %), 2024
Figure 5: Global: Migraine Drugs Market: Breakup by Route of Administration (in %), 2024
Figure 6: Global: Migraine Drugs Market: Breakup by Distribution Channel (in %), 2024
Figure 7: Global: Migraine Drugs Market: Breakup by Region (in %), 2024
Figure 8: Global: Migraine Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 9: Global: Migraine Drugs (Abortive Treatment) Market: Sales Value (in Million USD), 2019 & 2024
Figure 10: Global: Migraine Drugs (Abortive Treatment) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 11: Global: Migraine Drugs (Preventive Treatment) Market: Sales Value (in Million USD), 2019 & 2024
Figure 12: Global: Migraine Drugs (Preventive Treatment) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 13: Global: Migraine Drugs (Triptans) Market: Sales Value (in Million USD), 2019 & 2024
Figure 14: Global: Migraine Drugs (Triptans) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 15: Global: Migraine Drugs (Ergot Alkaloids) Market: Sales Value (in Million USD), 2019 & 2024
Figure 16: Global: Migraine Drugs (Ergot Alkaloids) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 17: Global: Migraine Drugs (NSAIDs) Market: Sales Value (in Million USD), 2019 & 2024
Figure 18: Global: Migraine Drugs (NSAIDs) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 19: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market: Sales Value (in Million USD), 2019 & 2024
Figure 20: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 21: Global: Migraine Drugs (Ditans) Market: Sales Value (in Million USD), 2019 & 2024
Figure 22: Global: Migraine Drugs (Ditans) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 23: Global: Migraine Drugs (CGRP mAbs) Market: Sales Value (in Million USD), 2019 & 2024
Figure 24: Global: Migraine Drugs (CGRP mAbs) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 25: Global: Migraine Drugs (Other Drug Types) Market: Sales Value (in Million USD), 2019 & 2024
Figure 26: Global: Migraine Drugs (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 27: Global: Migraine Drugs (Oral) Market: Sales Value (in Million USD), 2019 & 2024
Figure 28: Global: Migraine Drugs (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 29: Global: Migraine Drugs (Injectable) Market: Sales Value (in Million USD), 2019 & 2024
Figure 30: Global: Migraine Drugs (Injectable) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 31: Global: Migraine Drugs (Other Routes of Administration) Market: Sales Value (in Million USD), 2019 & 2024
Figure 32: Global: Migraine Drugs (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 33: Global: Migraine Drugs (Hospital-Based Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 34: Global: Migraine Drugs (Hospital-Based Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 35: Global: Migraine Drugs (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 36: Global: Migraine Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 37: Global: Migraine Drugs (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
Figure 38: Global: Migraine Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 39: North America: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 40: North America: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 41: United States: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 42: United States: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 43: Canada: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 44: Canada: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 45: Asia Pacific: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 46: Asia Pacific: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 47: China: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 48: China: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 49: Japan: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 50: Japan: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 51: India: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 52: India: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 53: South Korea: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 54: South Korea: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 55: Australia: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 56: Australia: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 57: Indonesia: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 58: Indonesia: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 59: Others: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 60: Others: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 61: Europe: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 62: Europe: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 63: Germany: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 64: Germany: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 65: France: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 66: France: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 67: United Kingdom: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 68: United Kingdom: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 69: Italy: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 70: Italy: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 71: Spain: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 72: Spain: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 73: Russia: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 74: Russia: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 75: Others: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 76: Others: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 77: Latin America: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 78: Latin America: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 79: Brazil: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 80: Brazil: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 81: Mexico: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 82: Mexico: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 83: Others: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 84: Others: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 85: Middle East and Africa: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 86: Middle East and Africa: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 87: Global: Migraine Drugs Industry: SWOT Analysis
Figure 88: Global: Migraine Drugs Industry: Value Chain Analysis
Figure 89: Global: Migraine Drugs Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Migraine Drugs Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: Migraine Drugs Market Forecast: Breakup by Treatment Type (in Million USD), 2025-2033
Table 3: Global: Migraine Drugs Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
Table 4: Global: Migraine Drugs Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
Table 5: Global: Migraine Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
Table 6: Global: Migraine Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 7: Global: Migraine Drugs Market Structure
Table 8: Global: Migraine Drugs Market: Key Players

Product Code: SR112025A2543

The global migraine drugs market size reached USD 4.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 6.5 Billion by 2033, exhibiting a growth rate (CAGR) of 4.06% during 2025-2033. The global migraine drugs market growth is significantly driven by the increasing assimilation of migraines, expanding knowledge of treatment processes, the development of therapies like CGRP-based drugs, the promotion of preventive treatments, and the rising expansion opportunities in emerging markets. Furthermore, North America represents the largest region due to the high prevalence of diseases in the area.

The migraine drugs market is going through enormous transformations as it continues to develop to address growing demand for effective medication. In addition, increased healthcare accessibility is greatly contributing to the growth of the migraine drugs market. As healthcare infrastructures continue to transform, especially in developed nations, availability to migraine medication is on the rise. Most nations are enhancing the availability of migraine medication through improved insurance coverage and reimbursement policies, so patients have access to newer and more effective treatments. Increased penetration of health insurance schemes, especially in developing markets, is also driving the demand for prescription drugs. In nations with rapidly developing healthcare infrastructure, access to migraine care is increasing, which is supporting the market growth.

Migraine Drugs Market Trends:

Growing Awareness and Diagnosis

The growing perception of migraine headaches and their very disabling kind of outcome is driving the demand for migraine drugs. Regarding its prevalence, the visitors remain undiagnosed or undertreated. Every year in June headache communities throughout the world work towards raining awareness about migraine among the masses. Secondly, with an increasing number of people realizing the need for effective treatments, they also increase the demand for treatments, driving the market growth. The Migraine Research Foundation states that over 39 million Americans suffer from migraines, with women being three times more prone to experiencing them than men. This growing recognition of migraines as a serious health issue encourages both migraine patients and medical practitioners to look for the most promising migraine treatment variation.

Advancements in Drug Development

Constant improvement in drug development and science is contributing to the growth of the market. In the pharma industry, research and development (R&D) of new treatments for migraine patients pose one of the significant workloads. This entails the application of drugs that are more effective, safer, and better in terms of modes of administration, such as utilization of new delivery systems or drug forms. Moreover, several clinical trials related to migraine therapy are either ongoing or planned, which only reinforces the perception that the research world is on its case in pursuit of the therapy. Each discovery is offering a new market niche where various alternatives are becoming accessible to patients, and the treatment is becoming improved, enhancing the living standard of migraineurs people. Research bodies are also conducting seminars and discussion events to make progress about migraine treatments. For instance, the American Academy of Neurology (AAN) conducted its 2025 annual meeting, held in San Diego, California from 5 April to 9 April 2025, to discuss about treatments for acute migraine.

Increasing Prevalence of Migraine Cases

The increasing number of migraine cases worldwide is driving the demand for migraine medication. Reports are continually coming in of increasing numbers of people having migraines because of factors like stress, lifestyle changes, and environmental factors. Increasing awareness about migraine as a disease condition is making more people go for treatment, thus driving the market for migraine medication. Health workers are increasingly seeing the necessity of effective, focused treatments, which is leading to the creation of new drugs specifically designed for migraine management. Also, since migraine crosses different ages but mainly impacts adults in their working age, the economic pressure of lost workdays is encouraging governments and the healthcare system to prioritize successful treatment. According to an article published by Medscape in 2024, In the United States, over 30 million individuals experience one or more migraine headaches annually. This steady rise in diagnosed cases is driving the need for pharmaceutical innovation within the migraine drugs market, with both preventive and acute treatments increasing usage.

Migraine Drugs Market Growth Drivers:

Increasing Healthcare Spending

The increasing healthcare spending globally is developing a favorable migraine drug market trend. The governments and the private approach are focusing increasingly funds on prevention and management of diseases such as migraines that are proven to short-termily impact healthcare systems and society. Additionally, global healthcare expenditure has been witnessing an ever-increasing trend of growth, mostly to address chronic conditions of disease management. Consequently, such individuals have greater access to the healthcare industry products and remedies, boosting the need for migraine medication. This trend is highest in the new markets, where migraines are becoming increasingly prevalent and this in turn creates particular opportunities for drug companies in terms of the therapies and treatments they offer for treating the symptoms of migraines.

Integration of Digital Solutions for Health

Growing incorporation of digital health solutions is one of the major drivers strengthening the market growth, which continues to grow. Mobile apps, wearables, and telemedicine platforms are becoming indispensable management tools for migraines. These digital platforms provide patients with the means to monitor different migraine triggers like food, stress levels, and environmental conditions, which are then treated on an individual basis. Through the ongoing tracking of migraine attacks and related symptoms, these technologies are allowing patients to better comprehend their condition and be more compliant with treatment. In addition, telemedicine platforms are facilitating distant consultations with healthcare professionals, which is increasing access to specialist services, especially in rural and underserved communities. These technologies are also allowing patients to take greater control of their condition, enhancing quality of life and overall therapeutic outcomes. With advances in digital health technologies, they augment the conventional drug therapies so that a more connected and data-informed care for migraines is made possible. The alignment of these technologies as a part of normal care is creating higher patient activation and will continue to drive the need for migraine drugs, especially ones that can be adjusted or tracked through these digital tools.

Shift Towards Preventive Therapies

There is a shift in the treatment of migraine away from acute relief and toward preventive therapy, which is critically impacting the development of the migraine drugs market. Historically, migraine therapies were directed largely at relief during an active attack. But as knowledge of migraine pathology has progressed, medical practitioners are placing greater emphasis on preventive therapy to decrease frequency as well as severity of attacks. This change is facilitated by increasing realization that recurrent migraines have a great effect on patients' quality of life, and preventive therapies can significantly enhance long-term effects. One of the most significant breakthroughs in preventive migraine therapies is the breakthrough for the creation of calcitonin gene-related peptide (CGRP) inhibitors. These biologics have proven enormous potential in attenuating the frequency of migraine attacks, providing long-term relief to patients suffering from chronic migraines. By specifically targeting certain molecular mechanisms implicated in migraine development, CGRP inhibitors bring with them a new era of migraine therapy, providing a targeted mechanism that provides improved efficacy and reduced side effects over existing therapies.

Migraine Drugs Market Segmentation:

Breakup by Treatment Type:

Abortive Treatment
Preventive Treatment

Preventive treatment accounts for the majority of the market share

Preventive dominates the migraine drugs market as it has proved to help reduce the frequency and intensity of migraine attacks, thereby improving the quality of life of the patients. As per the reports of the National Institutes of Health (NIH), 38% of migraineurs in the United States are looking for preventive treatment, whereas only a marginal section of them receives it. The former emphasizes the coherent unmet necessity for preventive methods. Driven by the fact that migraines are constant and that the best medicine against them is a preventative one, there has been an increasing trend among doctors and patients to use preventive medications for acute cases. So, this growing trend requires preventive approaches as the core of migraine management.

Breakup by Drug Type:

Triptans
Ergot Alkaloids
NSAIDs
Acetylcholine Inhibitors/ Neurotoxins
Ditans
CGRP mAbs
Others

Triptans hold the largest share of the industry

Based on the migraine drugs market forecast, triptans leads the market as migraine drugs are rooted in their ability to provide speedy relief from migraine symptoms, with special emphasis on headaches, neck pain, nausea as well as sensitivity to light and noise. For instance, as per the reports of the National Institute of Neurological Disorders and Stroke (NINDS) triptans, which has the highest prescription rate in the US, is the class of medication most commonly used by doctors for acute migraine treatment in the United States. They exert their effect by exciting sympathetic fibers in the blood vessels and by obstructing the passage of pain signals to the brain. With more than 20% of women and 9% of men with migraine experience in the U.S., there is still critical inpatient care gaps in effective acute treatments like triptans. Their growing popularity and widespread acceptance among healthcare providers prove their place in the migraine drugs market for acute attacks treatment, allowing patients trust their abilities to relieve pain.

Breakup by Route of Administration:

Oral
Injectable
Others

Oral represents the leading market segment

Oral route of administration drives the migraine drugs market value due to the convenience and ease of use of oral medications that allow patients to self-administer the treatment at home or on the go without medical supervision. According to the National Institute of Neurological Disorders and Stroke (NINDS), oral medications are the most frequently used treatment for migraine by healthcare providers. Its oral formulation also results in a faster onset of action compared to other routes, which facilitates relief for patients who are amid an acute migraine attack. Due to the existence of migraines among 20% of US women and 9% of men, there has been a rise in demand for oral treatments. The accessibility and effectiveness of these treatments make the dominance of the oral drug route applicable to the migraine drugs market.

Breakup by Distribution Channel:

Hospital-Based Pharmacies
Retail Pharmacies
Others

Hospital-based pharmacies are hospital-based and are situated in hospitals, offering medicinal products and pharmaceutical services to inpatients and outpatients. In the migraine drugs markets, hospital-based pharmacies play a vital role in making emergency departments or outpatient clinics accessible to acute migraine treatment patients. They have an expanded variety of medications in stock, that include triptans and other substances that are specific to the treatment of migraine. This ensures quick access and administration to acute migraine patients.

Retail pharmacies are pharmacies that are located in commercial and residential neighborhoods and offer prescription and over-the-counter drugs to the public. Alongside retail pharmacies, migraine patients who need both acute and preventive treatments turn to these pharmacies to access their drugs as it is a key point of care. They render counseling and support to patients, which is important for the correct usage of medicines and strict follow-up of treatment regimens. As retail pharmacies offer convenience that, they are emerging as key players in the distribution and availability of migraine medications by taking care of the migraine sufferers, even in distinct communities around.

Breakup by Region:

North America
- United States
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

North America leads the market, accounting for the largest migraine drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represented the largest market for migraine drugs.

North America dominates the market due to the high prevalence of diseases in the area, whereas the region boasts of a robust healthcare infrastructure and high healthcare spending, which form the backbone for market growth. Based on data from the U.S National Institute of Neurological Disorders and Stroke (NINDS), one out of every 10 Americans have migraines. Apart from that, North America has several big pharmaceutical companies that mainly deal with the development of anti-migraine drugs therefore setting up an environment that allows for research and product development. In addition, efforts by government agencies such as the US Food and Drug Administration (FDA) to ensure the speed of approval of drugs for the treatment of migraines also contribute to the region's market spreading. As a result, these forces keep North America at the top level of the worldwide migraine drugs industry.

Competitive Landscape:

The migraine drugs market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the migraine drugs industry include:

Abbott Laboratories
Allergan Plc (Abbvie Inc.)
Amgen Inc.
AstraZeneca Plc
Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
Eisai Co. Ltd.
Eli Lilly and Company
Endo International Plc
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co.
Novartis AG
Pfizer Inc.
Sanofi SA
Teva Pharmaceutical Industries Limited

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The key players in the migraine drugs market are constantly working on the research and development and commercialization stages and aim at fulfilling the needs of the migraine sufferers. Pharmaceutical concerns such as Amgen, Eli Lilly, and Teva Pharmaceutical Industries are among the industry players that are promoting cutting-edge therapies, for instance, calcitonin gene-related peptide (CGRP) inhibitors and gepants, for both treatment of acute migraines and prophylaxis. For instance, as per the migraine drugs market research U.S. National Institutes of Health (NIH) reports that the companies are currently enrolling participants for trials whose purpose is to evaluate the drugs for their safety and efficacy. The development of these respective initiatives, the rising of awareness about migraines in general, and access to proper treatment are also among the priorities of these companies.

Key Questions Answered in This Report

1.How big is the migraine drugs market?
2.What is the future outlook of migraine drugs market?
3.What are the key factors driving the migraine drugs market?
4.Which region accounts for the largest migraine drugs market share?
5.Which are the leading companies in the global migraine drugs market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Migraine Drugs Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Treatment Type

6.1 Abortive Treatment
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Preventive Treatment
- 6.2.1 Market Trends
- 6.2.2 Market Forecast

7 Market Breakup by Drug Type

7.1 Triptans
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Ergot Alkaloids
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 NSAIDs
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Acetylcholine Inhibitors/ Neurotoxins
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Ditans
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
7.6 CGRP mAbs
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
7.7 Others
- 7.7.1 Market Trends
- 7.7.2 Market Forecast

8 Market Breakup by Route of Administration

8.1 Oral
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Injectable
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

9.1 Hospital-Based Pharmacies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Retail Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 Abbott Laboratories
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
  - 15.3.1.3 Financials
  - 15.3.1.4 SWOT Analysis
- 15.3.2 Allergan Plc (Abbvie Inc.)
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
  - 15.3.2.3 SWOT Analysis
- 15.3.3 Amgen Inc.
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
  - 15.3.3.3 SWOT Analysis
- 15.3.4 AstraZeneca Plc
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
  - 15.3.4.3 Financials
  - 15.3.4.4 SWOT Analysis
- 15.3.5 Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
  - 15.3.5.3 Financials
  - 15.3.5.4 SWOT Analysis
- 15.3.6 Eisai Co. Ltd.
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
  - 15.3.6.3 Financials
  - 15.3.6.4 SWOT Analysis
- 15.3.7 Eli Lilly and Company
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
  - 15.3.7.3 Financials
  - 15.3.7.4 SWOT Analysis
- 15.3.8 Endo International Plc
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
  - 15.3.8.3 Financials
  - 15.3.8.4 SWOT Analysis
- 15.3.9 GlaxoSmithKline Plc
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
  - 15.3.9.4 SWOT Analysis
- 15.3.10 Johnson & Johnson
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
  - 15.3.10.3 Financials
  - 15.3.10.4 SWOT Analysis
- 15.3.11 Merck & Co.
  - 15.3.11.1 Company Overview
  - 15.3.11.2 Product Portfolio
  - 15.3.11.3 Financials
  - 15.3.11.4 SWOT Analysis
- 15.3.12 Novartis AG
  - 15.3.12.1 Company Overview
  - 15.3.12.2 Product Portfolio
  - 15.3.12.3 Financials
  - 15.3.12.4 SWOT Analysis
- 15.3.13 Pfizer Inc.
  - 15.3.13.1 Company Overview
  - 15.3.13.2 Product Portfolio
  - 15.3.13.3 Financials
  - 15.3.13.4 SWOT Analysis
- 15.3.14 Sanofi SA
  - 15.3.14.1 Company Overview
  - 15.3.14.2 Product Portfolio
  - 15.3.14.3 Financials
  - 15.3.14.4 SWOT Analysis
- 15.3.15 Teva Pharmaceutical Industries Limited
  - 15.3.15.1 Company Overview
  - 15.3.15.2 Product Portfolio
  - 15.3.15.3 Financials
  - 15.3.15.4 SWOT Analysis

片頭痛治療薬の市場レポート：治療タイプ別、薬剤タイプ別、投与経路別、流通チャネル別、地域別、2025～2033年

Migraine Drugs Market Report by Treatment Type, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033

片頭痛治療薬市場の動向

片頭痛治療薬市場の促進要因

目次

第1章 序文

第2章 調査範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の片頭痛治療薬市場

第6章 市場内訳：治療タイプ別

第7章 市場内訳：薬剤タイプ別

第8章 市場内訳：投与経路別

第9章 市場内訳：流通チャネル別

第10章 市場内訳：地域別

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格分析

第15章 競合情勢